Replimune Group, Inc. REPL announced positive top-line results from the primary analysis of the IGNYTE study on lead pipeline candidate RP1, in combination with Bristol Myers’ BMY blockbuster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback